To investigate detrusor function and cAMP activation as a possible target for detrusor overactivity in an experimental model lacking a key denitrosylation enzyme, Snitrosoglutathione reductase (GSNOR).
Introduction
The bladder has two physiological functions, urine storage and release, which describes its cyclic relaxation and contraction. These mechanisms work through an interaction between the nervous system and the urothelium and smooth muscle of the bladder [1] . The urothelium plays a sensory role and releases mediators to modulate smooth muscle tone [2] . Deregulation of mechanisms controlling contraction and relaxation can lead to bladder dysfunction such as detrusor overactivity [3] . Nitric oxide (NO) is considered to contribute to regulation of detrusor tone, but its role in the bladder remains controversial. Reduction in NO levels in the bladder using NO synthase (NOS) inhibitors or mice with targeted deletion of the gene for neuronal NOS (nNOS) results in bladder overactivity or a dilated hypertrophic bladder phenotype, respectively [4, 5] . However, NO donors have also been reported to cause small or inconsistent relaxations in the rat and mouse detrusor [6, 7] , and a complex response (relaxation and contraction) in pre-contacted human detrusor [8] , indicating that the role of NO in the bladder is still incompletely understood.
Several mechanisms are involved in protein activity regulation. S-nitrosylation, which is a post-translational modification of a cysteine residue on target proteins by NO, is a major mechanism affecting NO responses [9] . A wide variety of proteins are activated or inactivated by S-nitrosylation. This modification is regulated by S-nitrosoglutathione reductase (GSNOR), which mediates the denitrosylation process.
Excessive S-nitrosylation plays a role in many human diseases such as diabetes mellitus and pre-eclampsia [10] .
An analysis of the GSNOR-deficient (GSNOR À/À ) mouse penis showed increased levels of S-nitrosylated proteins, reduced NO bioavailability, endothelial NOS (eNOS) dysfunction, and increased oxidative damage, and these mice are predisposed to erectile dysfunction [11] . S-nitrosylation and its deregulation may also affect bladder homeostasis due to NO functional impairment. However, data remain poorly documented in this field.
We hypothesised that the bladder behaves similarly to the penis, both sharing common counter-regulatory mechanisms responsible for tissue relaxation and contraction involving NOS and RhoA/Rho-kinase pathways, respectively. The NOS pathway has been widely studied in the penis and plays a central role in erection physiology [12] . RhoA/Rho-kinase signalling is understood to modulate erectile tissue contraction in the penis [13] and to be involved in molecular mechanisms of the obstructed bladder [14] . Accordingly, we used GSNOR À/À mice to characterise bladder function, the aforementioned mediators and oxidative stress in the context of deregulated S-nitrosylation. Our hypothesis was that GSNOR À/À mice would exhibit bladder function abnormalities due to NOS and RhoA/Rho-kinase pathway deregulations. We conjectured that mechanisms controlling urinary bladder smooth muscle relaxation and contraction, represented respectively by NOS and RhoA/Rho-kinase pathways, are deranged in the context of deregulated Snitrosylation, leading to bladder dysfunction. We also assessed the effect of cAMP activation, which has a dual effect on nNOS and eNOS activation and RhoA/Rho-kinase inhibition [15, 16] in this experimental model.
Materials and Methods

Animals
Adult male (aged 3.5 months) homozygous GSNOR À/À and age-matched wild-type (WT) mice (C57BL/6, The Jackson Laboratory, Bar Harbor, ME, USA) were used. All experiments were approved by the Animal Care and Use Committee of the Johns Hopkins University School of Medicine and were conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
Study design
GSNOR
À/À (n = 30) and WT (n = 26) mice were treated for 7 days with colforsin daparoate (Abcam, Cambridge, UK) at 1 mg/kg/day intraperitoneally (i.p.) [17] or vehicle (saline). Colforsin is a water soluble analogue of forskolin that activates adenylyl cyclase to produce cAMP [18] . Forskolin was described to induce smooth muscle relaxation in urinary bladder from streptozotocin-treated mice [19] . We favoured colforsin rather than forskolin because of its water solubility to avoid dimethyl sulphoxide toxicity [20] . Moreover, colforsin has no effect on blood pressure (Karakus S, Musicki B, La Favor J, Burnett AL, unpublished work). At 24 h after the last injection of colforsin or vehicle, mice were used for cystometry or bladder collection for Western blot analyses.
Cystometry
In all, 24 mice (n = six/group) were anesthetised by i.p. injection of urethane (1.8 mg/kg), and a laparotomy was performed to expose the bladder. The bladder was emptied and a 25-G butterfly needle was inserted into the bladder dome. This needle was connected to a two-way tap, of which one port was connected to a pressure transducer and the other was connected to an infusion pump. Continuous cystometry was performed for 30 min by infusing saline in the bladder at 10 lL/min. The variables assessed were baseline pressure (lowest pressure between voids), threshold pressure (pressure at which voiding was initiated), peak pressure (maximum pressure observed during a micturition cycle), bladder capacity (maximum volume infused before urine expulsion, assessed at the end of the cystometry), compliance (change in volume/change in pressure), and the frequency of voiding and non-voiding contractions (NVCs). A voiding contraction was defined as a bladder pressure increase accompanied by saline expulsion from the urethra (micturition), whilst a NVC was not accompanied by micturition [21, 22] . Cystometry data were recorded using the DI-190 system (Dataq Instruments, Akron, OH, USA).
Western Blot analysis
In all, 32 mice (seven WT + vehicle, seven WT + colforsin, nine GSNOR À/À + vehicle, and nine GSNOR À/À + colforsin) were anaesthetised (100 mg/kg ketamine + 10 mg/kg xylazine, i.p.) for bladder collection. Bladders were immediately snap-frozen in liquid nitrogen and homogenised, as described previously [23] . Bladder homogenates were resolved on 7.5% or 4-20% Tris gels and transferred to polyvinylidene difluoride membranes. Membranes were probed with polyclonal antiphospho-eNOS (P-eNOS) on Ser-1177 antibody (Cell Signaling Technology, Beverly, MA, catalog number 9571S) at 1:450, polyclonal anti-phospho-nNOS (P-nNOS) on Ser-1412 antibody (gift from Dr. Solomon Snyder, Johns Hopkins Hospital, Baltimore, MD, USA) at 1:6000, polyclonal antiphosphorylated myosin phosphatase target subunit 1 phox antibody (BD Transduction Laboratories, catalog number 611414) at 1:1000 dilutions. These membranes were stripped and probed with antibodies for the index proteins, monoclonal anti-eNOS (BD Transduction Laboratories, catalog number 612392) at 1:500, polyclonal anti-nNOS (gift from Dr. Solomon Snyder) at 1:1000, polyclonal anti-MYPT-1 (Santa Cruz Biotechnology, catalog number sc-25618) at 1:1000, and monoclonal anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Santa Cruz Biotechnology, catalog number sc-32233) at 1:5000 dilutions. Bands were detected by horseradish peroxidase-conjugated antibodies (GE Healthcare, Piscataway, NJ, USA, catalog numbers NA931V and NA934V) and analysed using NIH Image software. P-eNOS, P-nNOS, and P-MYPT-1 densities were normalised relative to that of eNOS, nNOS, and MYPT-1, respectively. Other signals (ROCK I, ROCK II, gp91
phox , 4-HNE, nitrotyrosine, nNOS, and eNOS) were standardised to GAPDH. Results were expressed relative to values of WT mouse treated with vehicle. To verify that GAPDH expression was not affected by any of the treatments, the density of GAPDH in a set of samples (n = 9) was standardised per total proteins (Ponceau S staining). There was no difference in protein expression of GAPDH in bladders of WT-treated mice or GSNOR 
Statistical analysis
The sample sizes were not predetermined by statistical methods. Study design was based on experimental methodology and statistics of prior experimental work. Statistical analyses were performed using one-way ANOVA followed by the Tukey for multi-groups analyses of cystometric variables (Prism v.5, GraphPad Software, San Diego, CA USA). To compare samples on Western blots performed on different membranes, we used a modified t-test to compare the experimental groups with the normalised control ratio (WT + vehicle). All data were expressed as the mean (SEM) [24] . A P < 0.05 was considered to be statistically significant [25] . Cystometric variable results were coupled with effect size measure (Cohen's d) [26] .
Results
Voiding and NVC frequencies are increased in GSNO À/À mice and normalised by colforsin treatment Cystometric tracings showed that untreated GSNOR À/À mice had more voiding contractions and NVCs than untreated WT mice (Fig. 1) . Statistical analyses showed that untreated GSNOR À/À mice had significantly higher (P < 0.05) voiding contraction and NVC frequencies than WT mice (Fig. 2) . Further, Cohen's effect size values (d = 1.82 and 2.52, respectively) suggested high practical significance. There was no significant difference between GSNOR À/À and WT mice for the other cystometric variables. GSNOR À/À mice treated with colforsin showed significantly lower (P < 0.05) voiding contraction and NVC frequencies compared with GSNOR À/À mice treated with vehicle, and Cohen's effect size values (d = 1.85 and 1.28, respectively) suggested high practical significance. We did not observe a drug effect on cystometric variables of WT mice.
Phosphorylation of nNOS (Ser-1412) and eNOS (Ser-1177) is not changed in the GSNOR À/À mouse bladder and is not affected by colforsin treatment
There was no significant difference in the protein expressions of P-nNOS (Ser-1412), P-eNOS (Ser-1177), nNOS and eNOS in bladders of untreated GSNOR À/À compared to WT mice (Fig. 3 ). There was also no significant difference in these protein expression levels after colforsin treatment. Standardisation of treatment groups per control did not allow us to analyse the absolute magnitude of P-eNOS (Ser-1177) changes in a GSNOR À/À mouse bladder by colforsin treatment.
Protein expression of P-MYPT-1 (but not ROCK I and ROCK II) is increased in the GSNOR À/À mouse bladder and normalised by colforsin treatment ROCK I and II protein expression levels were not significantly different between untreated GSNOR À/À and WT mouse bladders. However, the ratio of P-MYPT-1 (Thr-696) to total MYPT-1, reflecting RhoA/Rho-kinase activity, was significantly higher (P < 0.05) in the bladders of GSNOR À/À mice compared to that of WT mice (Fig. 4) . Colforsin significantly lowered (P < 0.05) the protein expression level of P-MYPT-1 to levels similar to the levels found in WT mice, without any modification of ROCK I or II expression in bladders of GSNOR À/À mice. This treatment did not lead to any significant modification of ROCK I or II and P-MYPT-1 expressions in the bladders of WT mice.
Protein expression of NADPH oxidase subunit gp91 phox (but not oxidative stress markers) is increased in the GSNOR À/À mouse bladder and not affected by colforsin treatment Protein expression of NADPH oxidase catalytic subunit gp91 phox was significantly higher (P < 0.05) in the bladders of untreated GSNOR À/À mice compared to that of WT untreated mice (Fig. 5) . However, there was no significant difference in expressions of markers of oxidative stress, 4-HNE and nitrotyrosine, in the GSNOR À/À compared to WT untreated mouse bladders. There was no significant difference of gp91 phox expression in the bladders of GSNOR À/À mice after treatment with colforsin. There was also no significant difference in 4-HNE and nitrotyrosine expressions in the bladders of GSNOR À/À and WT mice after colforsin treatment.
Discussion
In the present study, we demonstrate a pivotal role of S-nitrosylation in bladder homeostasis that is linked with cAMP-regulated RhoA/Rho-kinase signalling of bladder contractility. The absence of regulation of S-nitrosylation in GSNOR À/À mice leads to detrusor overactivity in association with upregulated activity of the RhoA/Rho-kinase pathway (Fig. 6 ). The cAMP activation by colforsin reverses bladder dysfunction in GSNOR À/À mice conceivably by inhibiting abnormal RhoA/Rho-kinase signalling.
S-nitrosylation is a physiologically important posttranslational modification with functional consequences for signalling protein activity [9] . GSNOR is a key enzyme regulating this modification. To our knowledge, our present study is the first to report cystometric findings in GSNOR À/À mice characterised by abnormally increased voiding contraction and NVC frequencies, suggestive of detrusor overactivity [27] . This pathological model allowed us to explore the ameliorative effect of colforsin, a direct activator of adenylate cyclase that increases cAMP production. Also, MYPT-1 is one of the regulatory subunits of myosin-lightchain phosphatase (MLCP) that dephosphorylates the myosin light chain (MLC) [28] . This dephosphorylation initiates the relaxation process of smooth muscle cells. Conversely, the phosphorylation of MLC by MLC kinase (MLCK) leads to smooth muscle contraction [29] . MLCP activity is regulated through phosphorylation of MYPT-1 on Thr-696 by ROCK, which inhibits its phosphatase activity and thereby causes smooth muscle contraction [30] . Thus, P-MYPT-1 is a reflection of RhoA/Rho-kinase pathway activity, and its excessive levels in GSNOR À/À mouse bladders conceivably lead to excessive smooth muscle contraction and detrusor overactivity. A previous study reported that carbachol activates the RhoA/Rho-kinase pathway, leading to MYPT-1 phosphorylation at Thr-696 and sustained contraction in rat bladder smooth muscle cells [31] . In our present study, basal expression levels of the RhoA/Rho-kinase pathway were unchanged, but the increased level of phospho-MYPT-1 is consistent with increased activity of this pathway. Snitrosylation has been reported to regulate the activity of many enzymes including kinases and in the experimental context of GSNOR À/À mice, ROCK is conceivably nitrosylated as a consequence of deregulated denitrosylation [32] . It is known that in many conditions, such as ageing, RhoA/Rho-kinase activity is increased but its constituent expression levels are normal [33] . The implication of RhoA/ Rho-kinase pathway derangement in this pathological model supports the hypothesis that the bladder and penis share common mechanisms of regulation. In fact, RhoA/Rho-kinase signalling deregulation is also associated with erectile dysfunction [34, 35] .
gp91
phox is a subunit of NAPDH oxidase, which is a major source of reactive oxygen species, e.g. superoxide. Bladders of GSNOR À/À mice expressed higher levels of this subunit without any effect by colforsin. Evidence is lacking to affirm that increased gp91 phox expression is the consequence of lack of denitrosylation, but it is known that p47
phox , another subunit of NADPH oxidase, is regulated by S-nitrosylation [36] . Increased NADPH oxidase activity is understood to contribute to oxidative stress. However, 4-HNE and nitrotyrosine, which are biomarkers for oxidative stress and described to be increased in the GSNOR À/À mouse penis, were normal in the GSNOR À/À mouse bladder. One possible explanation for this finding is that gp91 phox does not contribute to NADPH oxidase activity in the bladder. In fact, it was described using gp91
phox -deficient mice that gp91
phox does not contribute to NADPDH oxidase activity in aortic smooth muscle cells [37] . The fact that oxidative stress markers, 4-HNE and nitrotyrosine, are normal here suggests that this elevation of gp91 phox may have a less likely impact on NADPH oxidase activity and consequently oxidative stress in the bladder. Moreover, it was described that NADPH oxidase gene expression is modulated by cAMP-dependent protein kinase A (PKA) in microglia and neurones [38] . Our interpretation that gp91 phox is not an accurate marker of NADPH oxidase activity in the bladder fits with the absence of modification of gp91 phox protein expression after cAMP activation by colforsin treatment. However, further screening of other oxidative stress markers and superoxide itself may be useful to affirm this assessment.
Protein expressions of both eNOS and nNOS isoforms and their phosphorylated isoforms (P-eNOS on Ser-1177 and PnNOS on Ser-1412, respectively) were not significantly different in GSNOR À/À and WT mouse bladders. These phosphorylation sites play major mediatory roles in penile erection. We conjectured first that they are also important in bladder function, although this was not shown in the present study. However, other NOS isoform phosphorylation sites may be involved as a result of RhoA/Rho-kinase pathway upregulation. Activation of RhoA/Rho-kinase signalling inhibits eNOS through phosphorylation on Thr-495, which dramatically decreases the levels of NO production leading to an increase of vascular tone [39] . It is also possible that NO levels are directly affected by S-nitrosylation of downstream effectors such as phosphodiesterase or soluble guanylyl cyclase (sGC) [40] . This situation is associated with normal levels of NOS isoforms but possibly abnormal NO signalling contributing to bladder overactivity.
The central role of cAMP formation in the penis and its relationship with RhoA/Rho-kinase pathway signalling [41] prompted us to use colforsin. cAMP activation has been considered to play a role in smooth relaxation involving badrenoceptors by reducing both calcium mobilisation and sensitivity of the contractile machinery to calcium [42] . However, a definitive role of cAMP-dependent badrenoceptor function remains uncertain. Its inhibition appears to have no effect on human detrusor function [43] . Nevertheless, we used a 24-h wash-out period to prevent this controversial relaxant effect and sought to elicit changes in specific mechanisms modulating the function of NOS and RhoA/Rho-kinase pathways. While its effect on NOS was neutral, this drug appeared to normalise RhoA/Rho-kinase activity as determined by P-MYPT-1 (Thr-696) measurement. Thus, the unphosphorylated and active form of MLCP dephosphorylates MLC and leads to bladder relaxation. The main mechanism of action of colforsin conceivably involves the upstream mediator RhoA. The phosphorylation of RhoA on Ser-188 by cAMP-dependent PKA, inducing its inhibition and consequently RhoA/Rho-kinase activity inhibition, leads to the normalisation of P-MYPT-1 levels [44, 45] . Furthermore, it was reported that PKA activation may inhibit protein S-nitrosylation [46] . This complementary effect may also contribute to the beneficial impact of colforsin.
We acknowledge several possible limitations of our present study. First, despite showing that MYPT-1 phosphorylation, as a reflection of RhoA/Rho-kinase activity, was increased in the GSNOR À/À mouse bladder, we did not measure Rhokinase activity directly to validate our hypothesis regarding the upregulation of RhoA/Rho-kinase [47] . It would also have been worthwhile to assess the effect of a Rho-kinase inhibitor, such as fasudil, on bladder function in our experimental model [48] ; however, the effectiveness of RhoA/Rho-kinase inhibition was previously described to reverse acetic acidinduced bladder overactivity in rats [49] . Furthermore, although we did not find any change in NOS phosphorylation (P-nNOS on Ser1412 and P-eNOS on Ser-1177), it remains possible that other phosphorylation sites on nNOS and eNOS are involved in bladder function. To clarify better these mechanisms, further studies in the bladder with analyses of other NOS phosphorylation sites and total NO levels may be done. Also, nitrosylation measurements of regulatory proteins, such as ROCK isoforms and sGC, are warranted in order to establish a cause-effect relationship between denitrosylation and bladder function. Considering the physiological role of the entire lower genitourinary tract, additional molecular studies may extend to the urethra. Finally, the systemic effects of colforsin, in particular cardiovascular effects, should be assessed to validate its safe use.
In conclusion, the present study reported for the first time, to our knowledge, an experimental model of detrusor overactivity related to GSNOR deficiency. The putatively decreased denitrosylation of ROCK leads to its upregulated activity and bladder overactivity, which we observed physiologically. This bladder dysfunction was reversed by cAMP activation, which inhibits RhoA/Rho-kinase signalling. These findings contribute to understanding the pathophysiology of bladder overactivity and may suggest a novel potential therapeutic approach.
